{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:27:33Z","timestamp":1787113653004,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ejca.2026.116897","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:39:42Z","timestamp":1781969982000},"page":"116897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumor treating fields: Will the evidence gap ever be filled?"],"prefix":"10.1016","volume":"244","author":[{"given":"Sruthi","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar Barjesteh van Waalwijk","family":"van Doorn-Khosrovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah G.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2026.116897_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116897_bib2","article-title":"FDA approves first-of-its-kind device to treat pancreatic cancer","year":"2026","journal-title":"FDA"},{"issue":"3","key":"10.1016\/j.ejca.2026.116897_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/neuonc\/now012","article-title":"TTFields: where does all the skepticism come from?","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2026.116897_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2017.01.005","article-title":"Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients","volume":"111","author":"Mehta","year":"2017","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.ejca.2026.116897_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2019.100189","article-title":"Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma","volume":"21","author":"Hayes","year":"2019","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.ejca.2026.116897_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102397","article-title":"LUNAR: Full Moon or Eclipse? An exploration into tumor treating fields in lung cancer","volume":"56","author":"Olivier","year":"2025","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.116897_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.mayocp.2013.05.012","article-title":"A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices","volume":"88","author":"Prasad","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.ejca.2026.116897_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030425","article-title":"Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review","volume":"3","author":"Boutron","year":"2006","journal-title":"PLOS Med"},{"issue":"26","key":"10.1016\/j.ejca.2026.116897_bib9","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMoa1305189","article-title":"Arthroscopic Partial Meniscectomy versus Sham Surgery for a Degenerative Meniscal Tear","volume":"369","author":"Sihvonen","year":"2013","journal-title":"New Engl J Med"},{"issue":"10115","key":"10.1016\/j.ejca.2026.116897_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial","volume":"391","author":"Al-Lamee","year":"2018","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ejca.2026.116897_bib11","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa2310610","article-title":"A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina","volume":"389","author":"Rajkumar","year":"2023","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2026.116897_bib12","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.amjmed.2018.07.030","article-title":"The necessity of sham controls","volume":"132","author":"Prasad","year":"2019","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.ejca.2026.116897_bib13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non\u2013small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2026.116897_bib14","article-title":"Early palliative care for adults with advanced cancer","author":"Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ejca.2026.116897_bib15","doi-asserted-by":"crossref","first-page":"e1373","DOI":"10.1093\/oncolo\/oyae050","article-title":"Early incorporation to palliative care (EPC) in patients with advanced non-small cell lung cancer: the PACO randomized clinical trial","volume":"29","author":"Allende","year":"2024","journal-title":"Oncologist"},{"issue":"13","key":"10.1016\/j.ejca.2026.116897_bib16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.2014.58.6362","article-title":"Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial","volume":"33","author":"Bakitas","year":"2015","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2026.116897_bib17","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejca.2026.116897_bib18","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.116897_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neo.2020.11.003","article-title":"Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression","volume":"23","author":"Patel","year":"2020","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.ejca.2026.116897_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101296","article-title":"Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers","volume":"15","author":"Jones","year":"2022","journal-title":"Transl Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2026.116897_bib21","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/0008-5472.CAN-22-0887","article-title":"The Mechanisms of Action of Tumor Treating Fields","volume":"82","author":"Moser","year":"2022","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2026.116897_bib22","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1109\/TBME.2020.2965883","article-title":"A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis","volume":"67","author":"Li","year":"2020","journal-title":"IEEE Trans Biomed Eng"},{"issue":"2","key":"10.1016\/j.ejca.2026.116897_bib23","doi-asserted-by":"crossref","DOI":"10.1063\/5.0197900","article-title":"Electrodynamic interaction between tumor treating fields and microtubule electrophysiological activities","volume":"8","author":"Li","year":"2024","journal-title":"APL Bioeng"},{"issue":"1","key":"10.1016\/j.ejca.2026.116897_bib24","article-title":"Tumor-treating fields dosimetry in glioblastoma: Insights into treatment planning, optimization, and dose-response relationships","volume":"6","author":"Mikic","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ejca.2026.116897_bib25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41420-018-0106-x","article-title":"Selective toxicity of tumor treating fields to melanoma: an in vitro and in vivo study","volume":"4","author":"Jo","year":"2018","journal-title":"Cell Death Discov"},{"issue":"9","key":"10.1016\/j.ejca.2026.116897_bib26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S1470-2045(23)00344-3","article-title":"Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2026.116897_bib27","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO-25-00746","article-title":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","volume":"43","author":"Babiker","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2026.116897_bib28","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116897_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115306","article-title":"Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50\/GOG-3029\/INNOVATE-3 pivotal phase 3 randomized study","volume":"219","author":"Vergote","year":"2025","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116897_bib30","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2025.08.066","article-title":"Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study","volume":"124","author":"Mehta","year":"2026","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"6","key":"10.1016\/j.ejca.2026.116897_bib31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116897_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116897_bib33","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44770","article-title":"Reporting of Physicians\u2019 or Investigators\u2019 Choice of Treatment in Oncology Randomized Clinical Trials","volume":"5","author":"Olivier","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ejca.2026.116897_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JOP.2016.017376","article-title":"Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"13","author":"Balaban","year":"2017","journal-title":"J Oncol Pract"},{"issue":"24","key":"10.1016\/j.ejca.2026.116897_bib35","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","article-title":"Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Sohal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2026.116897_bib36","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic Pancreatic Cancer: ASCO Guideline Update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10409","key":"10.1016\/j.ejca.2026.116897_bib37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2026.116897_bib38","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2026.116897_bib39","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116897_bib40","unstructured":"FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer. Accessed February 21, 2026. \u3008https:\/\/ascopost.com\/issues\/december-1-2014\/fda-approves-bevacizumab-plus-chemotherapy-for-platinum-resistant-recurrent-ovarian-cancer\/\u3009."},{"key":"10.1016\/j.ejca.2026.116897_bib41","unstructured":"WMA - The World Medical Association-WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Participants. Accessed February 21, 2026. \u3008https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/\u3009."},{"issue":"5","key":"10.1016\/j.ejca.2026.116897_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"10.1016\/j.ejca.2026.116897_bib43","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/annonc\/mdr492","article-title":"Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points","volume":"23","author":"Kay","year":"2012","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116897_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00474-6","article-title":"Tumor Treating Fields therapy in metastatic non-small-cell lung cancer","volume":"24","author":"Olivier","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116897_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00584-3","article-title":"Tumor Treating Fields therapy in metastatic non-small-cell lung cancer \u2013 Authors\u2019 reply","volume":"24","author":"Leal","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116897_bib46","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03377491?tab=history&a=1&b=149#version-content-panel."},{"key":"10.1016\/j.ejca.2026.116897_bib47","unstructured":"Approaches to Assessment of Overall Survival in Oncology Clinical Trials. August 18, 2025. Accessed April 5, 2026. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials\u3009."},{"key":"10.1016\/j.ejca.2026.116897_bib48","unstructured":"United States: National Archives and Records Administration: Office of the Federal Register. Determination of safety and effectiveness. In: Food and Drugs. Title 21. Office of the Federal Register, National Archives and Records Administration; 2025. Accessed March 8, 2026. https:\/\/www.govinfo.gov\/app\/details\/CFR-2025-title21-vol8\/CFR-2025-title21-vol8-sec860-7."},{"key":"10.1016\/j.ejca.2026.116897_bib49","unstructured":"The Least Burdensome Provisions: Concept and Principles. October 20, 2020. Accessed March 8, 2026. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/least-burdensome-provisions-concept-and-principles\u3009."},{"key":"10.1016\/j.ejca.2026.116897_bib50","unstructured":"Design Considerations for Pivotal Clinical Investigations for Medical Devices. October 8, 2023. Accessed April 6, 2026. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/design-considerations-pivotal-clinical-investigations-medical-devices\u3009."},{"key":"10.1016\/j.ejca.2026.116897_bib51","unstructured":"Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices, Amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and Repealing Council Directives 90\/385\/EEC and 93\/42\/EEC (Text with EEA Relevance.). Vol 117. 2017. Accessed March 8, 2026. \u3008http:\/\/data.europa.eu\/eli\/reg\/2017\/745\/oj\u3009."},{"key":"10.1016\/j.ejca.2026.116897_bib52","unstructured":"bes180222_optune_eng_version.pdf. Accessed March 8, 2026. \u3008https:\/\/www.tlv.se\/download\/18.3d5ca496161de47811d16065\/1519905690094\/bes180222_optune_eng_version.pdf\u3009."},{"issue":"11","key":"10.1016\/j.ejca.2026.116897_bib53","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1530\/EOR-23-0024","article-title":"Clinical investigations to evaluate high-risk orthopaedic devices: a systematic review of the peer-reviewed medical literature","volume":"8","author":"L\u00fcbbeke","year":"2023","journal-title":"EFORT Open Rev"},{"key":"10.1016\/j.ejca.2026.116897_bib54","unstructured":"Commission Implementing Regulation (EU) 2025\/2086 of 17 October 2025 Laying down, Pursuant to Regulation (EU) 2021\/2282 on Health Technology Assessment, Procedural Rules for the Interaction during, Exchange of Information on, and Participation in, the Preparation and Update of Joint Clinical Assessments of Medical Devices and in Vitro Diagnostic Medical Devices at Union Level, as Well as Templates for Those Joint Clinical Assessments. 2025. Accessed June 14, 2026. \u3008http:\/\/data.europa.eu\/eli\/reg_impl\/2025\/2086\/oj\u3009."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:15:42Z","timestamp":1787112942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":54,"alternative-id":["S0959804926006787"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116897","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor treating fields: Will the evidence gap ever be filled?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116897"}}